Thanks for that feedback Arthuros. The Bioshares article said that the 50/50 JV would split profits equally between the two companies, and that LBT would receive software license fees, so perhaps the annual license fee is retained fully by LBT. My take is that of the machine sales, some would go to the distributor and the remaining profit split consistent within the JV. Is that how it works? How does Hettich make $ otherwise?
FDA Approval, page-23
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $27.98M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.8¢ | 1.6¢ | $8.243K | 515.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 711167 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 142857 | 2 |
View Market Depth
| Last trade - 14.57pm 03/10/2024 (20 minute delay) ? |
| LBT (ASX) Chart |